Quarterly report · Q3
4361.TEDINET S100RZJW
Period2022-12-01 → 2023-08-31
Filed2023-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2022-12-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2021-12-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥216m | 2022-12-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥331m | 2021-12-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥209m | 2022-12-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥345m | 2021-12-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥208m | 2022-12-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥343m | 2021-12-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥158m | 2022-12-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥266m | 2021-12-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥158m | 2022-12-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥266m | 2021-12-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥8.2bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥5.9bn | at 2022-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.5bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.5bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.0bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥911m | at 2022-11-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥129.9 | 2022-12-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.73 | 2023-06-01 → 2023-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.07 | 2021-12-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.01 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.8% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-08-31 | ¥193m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-08-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-08-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-08-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-08-31 | ¥216m |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| jpcrp040300-q3r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2021-12-01 → 2022-08-31 | ¥308m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue | 2021-12-01 → 2022-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | revenue external | 2021-12-01 → 2022-08-31 | ¥29m |
| jpcrp040300-q3r_E01006-000Real Estate Leasingreportable segment | segment profit | 2021-12-01 → 2022-08-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-12-01 → 2022-08-31 | ¥6.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-12-01 → 2022-08-31 | ¥331m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 340
| Item | Context | Value | Unit |
|---|---|---|---|
| Other comprehensive income | Prior1YTDDuration | 9178000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 21974000 | JPY |
| Comprehensive income | Prior1YTDDuration | 274692000 | JPY |
| Comprehensive income | CurrentYTDDuration | 180124000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 274692000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 180124000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | － | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 6057641000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 28502000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6086144000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 6086144000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 6057641000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 28502000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 6086144000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 6086144000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 308258000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 22796000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 331055000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 331055000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 6142468000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 28727000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6171195000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 6171195000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 6142468000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 28727000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6171195000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 6171195000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 193369000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E01006-000RealEstateLeasingReportableSegmentMember | 23021000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 216390000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 216390000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |